Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
04/2003
04/03/2003WO2003026601A1 Oral composition for treating sensitive teeth
04/03/2003WO2003026590A2 Biological control of nanoparticles
04/03/2003WO2003026588A2 Methods and apparatus for extrusion of vesicles at high pressure
04/03/2003WO2003026581A2 Pharmaceutical compositions and methods for treating cancer
04/03/2003WO2003026577A2 P-amidobenzylethers in drug delivery agents
04/03/2003WO2003026570A2 Reduced toxicity cisplatin formulations and methods for using the same
04/03/2003WO2003026563A2 Conjugated anti-psychotic drugs and uses thereof
04/03/2003WO2003026492A2 Prevention and treatment of restenosis by local administration of drug
04/03/2003WO2003026481A2 Optically-absorbing nanoparticles for enhanced tissue repair
04/03/2003WO2003026445A1 Vitamin fortification of foodstuffs
04/03/2003WO2003026420A1 Bactericidal solutions
04/03/2003WO2003013478A8 Method of encapsulating an active substance
04/03/2003WO2003002133A3 Stabilisation of chlorophyll using medium chain triglyceride oils
04/03/2003WO2002102305A3 Adjuvant composition for mucosal and injection delivered vaccines
04/03/2003WO2002100418B1 Exothermic formulations for the treatment of ectoparasites
04/03/2003WO2002092049A3 System for delivering cosmetics and pharmaceuticals
04/03/2003WO2002089849B1 Compositions and delivery systems for administration of a local anesthetic agent
04/03/2003WO2002062330A3 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
04/03/2003WO2002057413A3 Peptides for activation and inhibition of delta pkc
04/03/2003WO2002045713A3 Orally-bioavailable formulations of fentanyl and congeners thereof
04/03/2003WO2002022174A9 A novel cationic lipopolymer as biocompatible gene delivery agent
04/03/2003WO2002011698A9 Novel compositions of minoxidil
04/03/2003WO2001091723A3 Fluorinated copolymer surfactants and use thereof in aerosol compositions
04/03/2003US20030066096 Comprises encapsulated green fluorescent protein, blue fluorescent protein, and/or phycobiliprotein; for use in toys, paints, slimy play material, textiles (clothing), bubbles, ballons, cosmetics, bath powders, lotions, and foods
04/03/2003US20030065389 Polyacrylamide hydrogel for arthritis
04/03/2003US20030065304 Medicament-loaded transdermal reservoir and method for its formation
04/03/2003US20030065134 Polyoxyalkylene derivative and process of producing the same
04/03/2003US20030065040 Hypotensive agents
04/03/2003US20030065024 Mixture of tocopherol and solvent; stabilization with surfactant
04/03/2003US20030065022 Mixture of paclitaxel and surfactant; anticancer agents
04/03/2003US20030065016 Nordihydroguaiartic derivatives for use in treatment of tumors
04/03/2003US20030065002 Analgesics; side effect reduction
04/03/2003US20030064984 Anticancer agents; side effect reduction
04/03/2003US20030064966 Bone disorders; osteoporosis
04/03/2003US20030064962 Protease inhibitor; viricide
04/03/2003US20030064961 Anaesthetic composition
04/03/2003US20030064960 Medicine for inducing osteogenesis
04/03/2003US20030064959 Mixture with polyacrylic acid and xanthan gumo
04/03/2003US20030064957 Reduced toxicity; enhance efficiency; side effect reduction
04/03/2003US20030064945 Modulation of gene expression; anticancer agents
04/03/2003US20030064943 High affinity TGFbeta nucleic acid ligands and inhibitors
04/03/2003US20030064933 Transdermal administration of ACE inhibitors
04/03/2003US20030064928 Therapeutic preparations for inhalation
04/03/2003US20030064922 G-CSF conjugates
04/03/2003US20030064482 Preparation of antiproliferative agent; obtain chemical intermediates, insert into reaction mixture, heat, remove protective groups, recover antiproliferative agent
04/03/2003US20030064133 Reducing particle size of lipophilic compound in presence of surface active agent; mixing with alkali metal alignate, adding to solution containing calcium to form beadlets; removing; rinsing with acidic solution; drying; coating
04/03/2003US20030064120 Method for relaxing human beings using personal care compositions
04/03/2003US20030064119 Methods and compositions for applying essential oils and naturally occurring compounds to plants to activate endogenous plant pathogen defense pathways
04/03/2003US20030064114 For vasodilatation and inhibition of transplant rejection
04/03/2003US20030064107 Taste masked pharmaceutical liquid formulations
04/03/2003US20030064106 For use in cosmetics, pharmacy and food additives
04/03/2003US20030064104 Shelf-stable, ready to use; to enhance delivery of active medicants/ingredients of pharmaceuticals, nutraceuticals, dietary supplements, therapeutics, diagnostics
04/03/2003US20030064102 Antimicrobial Composition
04/03/2003US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents
04/03/2003US20030064096 Flavored gelatin capsule and method of manufacture
04/03/2003US20030064095 Microfabricated nanopore device for sustained release of therapeutic agent
04/03/2003US20030064094 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (COPD)
04/03/2003US20030064093 For therapeutic and cosmetic application
04/03/2003US20030064092 Pharmaceutical composition containing two active ingredients for smoking cessation
04/03/2003US20030064088 Surgically implantable and sealable drug delivery device that upon contact of its contents via an interface window or port with an organ or tissue exposes a therapeutic agent to organ or tissue surface, allowing a controlled, selective diffusion
04/03/2003US20030064078 Vaccines
04/03/2003US20030064074 Recombinant gelatins in vaccines
04/03/2003US20030064052 Useful for maintaining controlled and reliable dosage of the therapeutic agent via pulmonary delivery
04/03/2003US20030064050 High drug efficiency, high drug carrying capacity, good water solubility, good stability on storage, reduced toxicity, and improved anti-tumor activity in vivo
04/03/2003US20030064036 Coating and binding agent for pharmaceutical formulations with improved storage stability
04/03/2003US20030064029 Use of a bioactive agent in manufacture of a medicament for pulmonary delivery whereby medicament comprises perforated microstructures which are aerosolized using an inhalation device to provide aerosolized medicament
04/03/2003US20030062292 Process for the production or medicinal white oil using MCM-41 sulfur sorbent
04/03/2003CA2778208A1 Delivery system for biological component
04/03/2003CA2461898A1 Biological control of nanoparticles
04/03/2003CA2461870A1 Modified release dosage forms
04/03/2003CA2461865A1 Dosage form containing a confectionery composition
04/03/2003CA2461705A1 Coadministration of transport protein with conjugated cobalamin to deliver agents
04/03/2003CA2461702A1 Methods and apparatus for extrusion of vesicles at high pressure
04/03/2003CA2461693A1 Dosage form for treatment of diabetes mellitus
04/03/2003CA2461684A1 Modified release dosage forms
04/03/2003CA2461682A1 Composite dosage forms
04/03/2003CA2461663A1 Conjugated anti-psychotic drugs and uses thereof
04/03/2003CA2461656A1 Modified release dosage forms
04/03/2003CA2461653A1 Edible composition and dosage form comprising an edible shell
04/03/2003CA2461630A1 Organoleptically acceptable intraorally disintegrating compositions
04/03/2003CA2461616A1 Composite dosage forms having an inlaid portion
04/03/2003CA2461504A1 Polymers with structure-defined functions
04/03/2003CA2461421A1 Material consisting of at least a biodegradable polymer and cyclodextrins
04/03/2003CA2461351A1 Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
04/03/2003CA2461295A1 Vitamin fortification of foodstuffs
04/03/2003CA2461219A1 Reduced toxicity cisplatin formulations and methods for using the same
04/03/2003CA2461044A1 Intraorally disintegrating valdecoxib compositions
04/03/2003CA2461042A1 Process for the preparation of fast dissolving dosage form
04/03/2003CA2460787A1 Prevention and treatment of restenosis by local administration of drug
04/03/2003CA2460780A1 Autologous growth factor cocktail composition, method of production and use
04/03/2003CA2459976A1 Opioid formulations having reduced potential for abuse
04/03/2003CA2447984A1 Dosage forms having an inner core and outer shell with different shapes
04/03/2003CA2446904A1 Delivery of drug esters through an inhalation route
04/03/2003CA2446760A1 Dosage forms having an inner core and outer shell
04/03/2003CA2446759A1 Modified release dosage forms
04/02/2003EP1298145A1 Dds compound and process for the preparation thereof
04/02/2003EP1297843A1 Method of photoreduction of hemoglobin vesicles
04/02/2003EP1297842A1 Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
04/02/2003EP1297838A1 Pralmorelin-containing nasal drop preparations
04/02/2003EP1297836A1 COMPOSITIONS CONTROLLING RELEASE pH RANGE AND/OR SPEED
1 ... 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 ... 1712